Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market

Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market by Cancer Type (Exocrine and Endocrine), Treatment (Surgery, Chemotherapy, Radiation Therapy, and Targeted Therapy), Diagnostics (Imaging, Biopsy, Endoscopy, and Others), and Geography - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1575
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 199
  • Format:
  • Pub. Date: Upcoming
  • Share:

The Asia Pacific pancreatic cancer therapeutics & diagnostics market size is estimated to register a significant CAGR during the forecast period, 2021–2028. Growth of the market is attributed to the high demand for diagnostic testing and treatment.

Pancreatic cancer starts from the pancreatic tissues. The pancreas produces enzymes that aid digestion and regulate blood sugar levels. The pancreatic cancer rapidly stretches to surrounding organs. People with a pancreatic cyst or a family history of pancreatic cancer are often detected at an early stage. Diabetes is the most prevalent symptom of pancreatic cancer, followed by weight loss and discomfort in the upper abdomen that travels to the back.

Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market Key Takeaways

The market for pancreatic cancer diagnostics is predicted to develop faster as the prevalence of pancreatic cancer rises. Furthermore, rising illness awareness and concern, increasing healthcare spending, technical breakthroughs and new product innovation, are estimated to propel the pancreatic cancer diagnostics market during the forecast period.

The Covid-19 pandemic affected the demand and supply of Asia Pacific pancreatic cancer therapeutics & diagnostics market. Lockdown across the globe, supply chain disorders, and oscillating supply of raw materials forced manufacturers to shut down production leading to unfortunate decline in market growth. Launch of vaccines to combat the Covid-19 pandemic is expected to contribute to the market growth over the forecast period.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing demand for diagnostic testing and treatment is expected to propel the market in the coming years.
  • Increasing healthcare expenditure is key factor fueling the market during the forecast period.
  • The high cost of treatment and diagnostics, as well as therapy-related adverse effects, are projected to hinder the market growth.
  • Limited treatment options act as major challenge that can hamper the market expansion during the forecast period.
  • Technological advancements and medicinal improvements are anticipated to offer immense opportunities for the market players.

Scope of the Report

The report on the Asia-Pacific pancreatic cancer therapeutics & diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Pancreatic Cancer Therapeutics & Diagnostics Market - Asia-Pacific Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Cancer Type (Exocrine and Endocrine), Treatment (Surgery, Chemotherapy, Radiation Therapy, and Targeted Therapy), Diagnostics (Imaging, Biopsy, Endoscopy, and Other diagnostic tests)

Geographical Scope

China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific.

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Eli Lilly and Company, Bristol-Myers Squibb, Pfizer Inc, Novartis, and F. Hoffman-La Roche AG.

Market Segment Insights

The exocrine segment is projected to hold a major market share

On the basis of cancer type, the Asia Pacific pancreatic cancer therapeutics & diagnostics market is bifurcated into exocrine and endocrine. The exocrine segment is expected to represent a key share of the market during the forecast period owing to rising number of patients having exocrine type of cancer. Exocrine cancer accounts for around 93 percent of pancreatic cancer. They begin in the pancreas' exocrine cells, which generate enzymes that aid digestion. Exocrine pancreatic cancer arises from the exocrine gland and ducts of the pancreas, which are made up of exocrine cells. In the duodenum, the exocrine gland secretes enzymes that aid in the breakdown of carbs, lipids, proteins, and acids.

Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market By Cancer Type

The radiation therapy segment is anticipated to expand at a high CAGR

Based on treatment, the Asia Pacific pancreatic cancer therapeutics & diagnostics market is segregated into surgery, chemotherapy, radiation therapy, and targeted therapy. The radiation therapy segment is expected to represent a key share of the market during the forecast period. Radiation treatment helps to slow the growth of pancreatic cancers and potentially decrease them.

Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market By Treatment

The imaging segment is expected to grow at a rapid pace

On the basis of diagnostics, the market is divided into imaging, biopsy, endoscopy, and others. The imaging segment is expected to constitute a key share of the market during the forecast period owing to technological developments of imaging techniques with respect to pancreatic cancer. It is one of the deadliest malignancies, and is a serious public health issue in the twenty-first century. Because early-stage illness is typically quiet or appears with non-specific symptoms that go unnoticed, diagnosis is almost reliant on imaging modalities. Medical imaging advancements have enhanced the capacity to diagnose and treat young diseases like cancer. Computed tomography (CT) is the most regularly utilized imaging tool for pancreatic cancer detection and staging. Imaging enables doctors to detect cancers in their early stages, resulting in better patient outcomes. As diseases are most curable when identified early, this efficient technology has the potential to save lives.

China is expected to dominate the market

On the basis of geography, the Asia-Pacific pancreatic cancer therapeutics & diagnostics market is categorized as China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific. China is anticipated to dominate the market at a high CAGR during the forecast period. Factors such as high prevalence of pancreatic cancer, substantial unmet requirements, and presence of emerging countries like India and China in the region are anticipated to boost the market.

Segments

Segments Covered in the Report
The Asia-Pacific pancreatic cancer therapeutics & diagnostics market has been segmented on the basis of

Cancer Type
  • Exocrine
  • Endocrine
Treatment
  • Surgery
  • Chemotherapy
  • Radiation therapy
  • Targeted therapy
Diagnostics
  • Imaging
  • Biopsy
  • Endoscopy
  • Other diagnostic tests
Geography
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific.
Key Players
  • Eli Lilly and Company
  • Bristol-Myers Squibb
  • Pfizer Inc
  • Novartis
  • F. Hoffman-La Roche AG

Competitive Landscape

Key players competing in the Asia-Pacific pancreatic cancer therapeutics & diagnostics market include Eli Lilly and Company, Bristol-Myers Squibb, Pfizer Inc, Novartis, and F. Hoffman-La Roche AG.

Some of these players are using several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.

Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market By Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pancreatic Cancer Therapeutics & Diagnostics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Pancreatic Cancer Therapeutics & Diagnostics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Pancreatic Cancer Therapeutics & Diagnostics Market - Supply Chain
  4.5. Global Pancreatic Cancer Therapeutics & Diagnostics Market Forecast
     4.5.1. Pancreatic Cancer Therapeutics & Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Pancreatic Cancer Therapeutics & Diagnostics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Pancreatic Cancer Therapeutics & Diagnostics Market Absolute $ Opportunity
5. Global Pancreatic Cancer Therapeutics & Diagnostics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Pancreatic Cancer Therapeutics & Diagnostics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Pancreatic Cancer Therapeutics & Diagnostics Demand Share Forecast, 2019-2026
6. North America Pancreatic Cancer Therapeutics & Diagnostics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Pancreatic Cancer Therapeutics & Diagnostics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Pancreatic Cancer Therapeutics & Diagnostics Demand Share Forecast, 2019-2026
7. Latin America Pancreatic Cancer Therapeutics & Diagnostics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Pancreatic Cancer Therapeutics & Diagnostics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Pancreatic Cancer Therapeutics & Diagnostics Demand Share Forecast, 2019-2026
8. Europe Pancreatic Cancer Therapeutics & Diagnostics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Pancreatic Cancer Therapeutics & Diagnostics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Pancreatic Cancer Therapeutics & Diagnostics Demand Share Forecast, 2019-2026
9. Asia Pacific Pancreatic Cancer Therapeutics & Diagnostics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Pancreatic Cancer Therapeutics & Diagnostics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Pancreatic Cancer Therapeutics & Diagnostics Demand Share Forecast, 2019-2026
10. Middle East & Africa Pancreatic Cancer Therapeutics & Diagnostics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Pancreatic Cancer Therapeutics & Diagnostics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Pancreatic Cancer Therapeutics & Diagnostics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Pancreatic Cancer Therapeutics & Diagnostics Market: Market Share Analysis
  11.2. Pancreatic Cancer Therapeutics & Diagnostics Distributors and Customers
  11.3. Pancreatic Cancer Therapeutics & Diagnostics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Eli Lilly and Company Bristol-Myers Squibb Pfizer Inc Novartis F. Hoffman-La Roche AG
Segments Covered in the Report
The Asia-Pacific pancreatic cancer therapeutics & diagnostics market has been segmented on the basis of

Cancer Type
  • Exocrine
  • Endocrine
Treatment
  • Surgery
  • Chemotherapy
  • Radiation therapy
  • Targeted therapy
Diagnostics
  • Imaging
  • Biopsy
  • Endoscopy
  • Other diagnostic tests
Geography
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific.
Key Players
  • Eli Lilly and Company
  • Bristol-Myers Squibb
  • Pfizer Inc
  • Novartis
  • F. Hoffman-La Roche AG

Key players competing in the Asia-Pacific pancreatic cancer therapeutics & diagnostics market include Eli Lilly and Company, Bristol-Myers Squibb, Pfizer Inc, Novartis, and F. Hoffman-La Roche AG.

Some of these players are using several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.

Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market By Key Players

Buy Report